Recent e vide nce sugge sts that nonste roidal antiin¯ammatory drugs (NSAIDs) may pre ve nt colore ctal cancer. The mechanism of action of NSAIDs in che mopre vention is unknown but may be linke d to the ir effe ct on mucosal prostaglandin le vels. Leve ls of ® ve major prostaglandin metabolite s were measure d by gas chromatograp hy± mass spectrome try in biopsy specime ns of¯at re ctal mucosa from four patie nts with familial ade nomatous polyposis (FAP) before and afte r sulindac the rapy and from ® ve healthy individuals. The prostaglandin prese nt at highe st conce ntration in re ctal mucosa from FAP and control subje cts was prostaglandin E 2 . The concentration of thromboxane B 2 alone was signi® cantly elevate d in FAP patie nts compare d to controls (P 5 0.016). In FAP patie nts tre ate d with sulindac, all prostaglandin metabolite leve ls were signi® cantly re duced compare d to pre treatme nt le vels (P , 0.05) e xce pt prostaglandin D 2 (P 5 0.07) . Prostaglandins D 2 , E 2 , F 2a , and 6-ke to-F 1a le ve ls also were signi® cantly re duced in FAP patie nts on sulindac compare d to he althy controls (P , 0.05) . Howeve r, inte rpatie nt he te roge ne ity of re sponse to sulindac was evide nt with change s ranging from 1 19% to 2 89% , and the patie nt with the gre ate st re ductions afte r sulindac de velope d colore ctal cance r after 35 months of therapy. Sulindac treatme nt, at drug dose s shown to re gre ss colore ctal ade nomas in FAP patie nts, has he te roge ne ous effe cts on the leve l of major prostaglandins in the ir re ctal mucosa and may not pre ve nt colore ctal cance r due to uncoupling of prostaglandin leve ls and carcinoge nesis.
studie s (10, 11) , and re gre ss ade nomas in patie nts with familial ade nomatous polyposis (12± 16) .
The mechanism of action of NSAIDs in the chemopre vention of colore ctal cance r is unknown but may be linke d to the effe ct of the se age nts on mucosal prostaglandin leve ls. Earlie r evide nce sugge sts that prostaglandins may modulate tumor cell growth and facilitate tumor cell progre ssion (17± 19) . Prostaglandins, particularly prostaglandin E 2 (PGE 2 ), are produced in incre ase d amounts in human colonic tumor cells (20, 21) . In anim al mode ls of colore ctal cance r carcinoge ne sis, normal-appe aring mucosa in cancerbearing animals has increased le vels of PGE 2 (22) compare d to controls, and PGE 2 is highe r in the tumor tissue compare d to the mucosa in carcinoge ntre ated animals (23) . In humans, tissue concentrations of PGE 2 are signi® cantly increased in colore ctal ade nomas compare d to¯at mucosa in controls, and eve n greate r le vels were found in malignant polyps and cance rs (24, 25 ) . An increase of PGE 2 is also found in¯at colore ctal mucosa of patie nts with adenocarcinoma (24) . O n the othe r hand, prostaglandin le ve ls are found to be inde pe nde nt of the effe cts of NSAIDs in studie s of experiment colore ctal carcinoge ne sis and growth of colore ctal cancer cell line s (26, 27) .
In patie nts with familial ade nomatous polyposis (FAP), sulindac has be en shown to re sult in regression of colore ctal ade nomas, but limite d data e xist on the in¯uence of NSAIDs on colore ctal mucosal prostaglandin le vels (13, 28, 29) . There fore , to unde rstand the e ffect of NSAIDs on a pro® le of colore ctal mucosal prostaglandin le vels, we utilize d gas chromatography and mass spectrometry, a methodology not pre viously e mploye d, to measure the concurre nt levels of ® ve major prostaglandin metabolite s in biopsy spe cimens. Flat mucosa of patie nts with FAP be fore and afte r sulindac tre atme nt and of he althy controls was studie d.
MATERIALS AND METHODS
Subjects. The study population consisted of four Caucasian FAP patients with previous colectomy and ileorectal anastomosis who had ade nomas in the rectum (mean age 37.4 6 11 SD; two men, two women). Mucosal prostaglandin leve ls were me asured in these patients imme diate ly before the initiation of sulindac tre atme nt and afte r therapy with sulindac 150 mg orally twice a day for three months. Polyp regre ssion was noted in all patie nts afte r three months of the rapy. However, one of the patients (patie nt 4 in Figure 1 below) deve loped rectal cancer while on sulindac 35 months afte r initiation of the drug. The control population was ® ve othe rwise he althy Caucasian individuals with normal colonoscopic e xaminations performed for the evaluation of abdominal pain or hematoche zia or for risk of FAP (persons at risk for FAP had negative APC gene te sts) (me an age 26.7 6 15 SD; two men; three women).
All patie nts were prepared for the endoscopic procedure with a clear liquid diet and oral cathartic solution. Enemas that could in¯uence mucosal biochemistry we re not give n. In each patient, six rectal mucosal biopsies were taken from at mucosa 10 ± 12 cm from the anal ve rge to minimize potential diffe rences that might occur from specimens taken at diffe rent colorectal sites. Four rectal mucosal specimens we re snap frozen in liquid nitrogen for prostaglandin analysis, and two were placed in formalin for histopathologic examination. Histopathology showed colorectal mucosa without ade nomatous epithelium or aberrant crypt foci in all nine individuals.
Specimen Processing. Rectal mucosal biopsy specimens we re analyze d for prostaglandin D 2 (PGD 2 ), prostaglandin E 2 (PGE 2 ), prostaglandin F 2 a (PGF 2 a ), thromboxane B 2 (TXB 2 ), and the principal prostaglandin I 2 me tabolite, 6-ke to-prostaglandin F 1 a (6-ke to-F 1a ). Brie¯y, specimens we re rinsed with cationic-fre e Hanks' balanced salt solution (HBSS; containing 138 mM NaCl, 5 mM KCl, 4 mM NaHCO 3 , 5.6 mM D-glucose, 0.3 mM Na 2 HPO 4 , and 0.3 mM KH 2 PO 4 ). Samples we re the n manually homogenized in a glass microhomogenizer in 50 m l HBSS containing 1 mM CaCl 2 . The homogenizer was then rinsed with 60 m l HBSS containing 1 mM CaCl 2 . Of the combined 110 m l homogenate, 10 m l was used to dete rmine protein concentration by the Bradford protein assay (Bio-Rad). The remaining 100 m l was then incubated at 37°C for 15 min, followed by the addition of 50 m l of deute rated prostaglandin standards. The sample was the n e qually divided. Following the addition of 250 m l acetone to e ach half, the specimens were dried under a steady stream of nitrogen gas.
At the point of complete drying, 25 m l oximating reage nt (2% O-me thoxylamine HCl in pyridine) was added immediate ly to the sample. Each vial was then sealed with a Te¯on-lined closure, and the contents we re vigorously mixe d with the use of a vorte x mixe r and left at room temperature for 12± 16 hr for oximation of the carbonyl moietie s of PGD 2 , PGE 2 , TXB 2 , and 6-ke to-F 1a . The samples we re stored at 2 20°C until delivery to the mass spectrometry laboratory for quantitation of prostaglandin levels.
Determ in ation of Prostaglan d ins by GC-MS.
Samples stored at 2 20°C we re ® rst brought to room tempe rature,
followed by e vaporation of the pyridine solvent of the oximating reage nt under a nitrogen stream. Subsequent to evaporation of pyridine, the residue of e ach vial was treate d with reage nts for synthesis of the penta¯uorobenzyl e ste r± trimethylsilyl e the r derivatives of the prostanoid analyte s for gas chromatography± mass spe ctrometric (GC-MS) analysis as described (30, 31) . Brie¯y, a Finnagan MAT SSQ710 combined gas chromatograph± mass spectrometer (Finnigan MAT, San Jose, California) was operate d under electron capture negative conditions. Characte ristic M 2 , 2 181 fragme nt ions of e ach of the prostaglandin derivative s and those of the deuterate d prostaglandin analogs used as internal standards were monitored simultaneously. The levels of e ach of the prostaglandins in the samples we re based upon the use of known quantities of deute rated prostaglandins employed as internal standards. Other instrument pa-rame te rs for combined GC-MS analysis and commercial sources of reage nts for derivatization have bee n reported previously (30, 31) . Statistical Analysis. Diffe rences in prostaglandin levels betwee n controls and FAP patients before sulindac tre atme nt we re compared by Mann-Whitney U te st. Reductions in FAP patie nts afte r sulindac tre atme nt as compared to baseline we re compared by paired one-tailed Student' s t test. Signi® cance betwe en groups was de® ned as P , 0.05.
RESULTS
O f the ® ve prostaglandin metabolite s measure d (Table 1 and Figure 1 ), PGE 2 was pre sent at the highe st conce ntration in re ctal mucosa from FAP patie nts be fore sulindac treatment and from controls. The concentration of TXB 2 was statistically e levate d in untre ated FAP patie nts compare d to controls (P 5 0.016) , but the conce ntration s of PGD 2 , PGE 2 , PGF 2a , and 6KF 1a were not statistically diffe re nt.
In FAP patie nts tre ated with sulindac for three months, all prostaglandin metabolite leve ls except PGD 2 were statistically signi® cantly lowe r than be fore the rapy (P , 0.05) ; the concentration of PGD 2 le vel was marginally lower (P 5 0.07) . Me an PGD 2 , PGE 2 , PGF 2a , and 6-ke to-F 1a conce ntrations in FAP patients treated with sulindac also were signi® cantly reduce d compare d to those of healthy controls (P , 0.05) . The se e ffe cts corre late d with complete adenoma regre ssion in all patie nts. Mean change from base line afte r sulindac the rapy was found to decline for all prostaglandins (Table 1) . When inte rpatie nt variation was conside re d, patie nt 1 ( Figure 1 ) showe d change s from base line ranging from 1 19% for PGD 2 to 2 34% for PGF 2 . The gre atest re sponse to sulindac the rapy occurre d in patie nt 4 (range : 2 89% for PGE 2 to 2 82% for PGF 2 ), who subse que ntly de velope d an ulce rating¯at re ctal ade nocarcinom a but no ade nomatous polyps while on sulindac the rapy for 35 months (Figure 2A and B) .
DISCUSSION
We e xamine d a pro® le of prostaglandin metabolite s in human colore ctal mucosa. In contrast to othe r inve stigators who have utilize d radioimmunoa ssay to dete rmine colore ctal mucosal prostaglandin leve ls (13, 28, 29, 32) , we employe d gas chromatograph y couple d with mass spectrometry. The accuracy of radioim munoassay is de pende nt upon antibody spe ci® city, and the limitation of this approach is e vide nce d by the wide variation of absolute value s for prostaglandin le vels betwe en publishe d studie s. In contrast, our methodology allowe d the conve nie nt, simultane ous, and accurate measure ment of a se rie s of prostaglandins. Dif® cultie s with metabolite stability are minimize d by the use of inte rnal standards e mploye d in this technique . Examination of a mucosal prostaglandin pro® le may also have future importance in unde rstanding which of the se compounds might best serve as biom arkers of human colore ctal carcinoge nesis and as indicators of patie nt compliance with medication in clinical trials. More over, this approach may also be use ful in testing compounds thought to act via pathways inde pe nde nt of prostaglandin synthe sis. In our study, PGE 2 was pre sent in greate st concentration in re ctal mucosa not only in those affe cted by FAP but also in healthy individuals, a ® nding not pre viously reporte d. O f note , a signi® cantly highe r le ve l of TXB 2 , but not othe r prostaglandins, was found in the¯at mucosa of FAP patie nts compare d to he althy controls. The se ® ndings contrast with those in anim al mode ls of colore ctal cance r, in which carcinoge n-tre ate d rats have persiste ntly highe r le ve ls of PGE 2 in normal¯at mucosa compare d to control anim als (23) . The signi® cance of increased TXB 2 le ve ls in FAP patie nts awaits furthe r inve stigation.
We found that sulindac take n orally by FAP patients signi® cantly decrease d mean rectal mucosal le ve ls of all the major prostaglandin metabolite s e xcept PGD 2 (although PGD 2 had a marginally significant decrease, P 5 0.07) . This ® nding is consiste nt with the work of Rigau e t al (13) , who measure d PGE 2 and 6-ke to-F 1a in¯at colore ctal mucosa of FAP patie nts before and after sulindac tre atme nt and found a signi® cant de crease in both prostaglandins afte r sulindac the rapy. Winde e t al (28) and Nuge nt et al (29) analyze d¯at colore ctal mucosal PGE 2 and PGF 2a and also note d a signi® cant re duction in the PGE 2 after tre atme nt. Importantly, in our study, sulindac administration signi® cantly decreased le vels of seve ral prostaglandins (D 2 , E 2 , F 2 , 6-ke to-F 1a ) be low concentrations in healthy control subje cts. These effe cts corre late d with the re gre ssion of colore ctal adenomas in the sulindac-tre ate d FAP patie nts.
Some inve stigators have indicate d that colore ctal prostaglandin le ve ls are not affected in patie nts taking similar NSAID dose s that cause tumor re gre ssion. Although our data de monstrate a signi® cant de crease in mean prostaglandin le ve ls in rectal mucosa following sulindac tre atme nt, substantial interpatie nt he teroge ne ity was note d. Patie nt 1 showe d little or no reduction in se veral prostaglandin leve ls in the face of regre ssion of ade nomas and high medication compliance . Of e ven greate r inte rest, patie nt 4, who had the gre atest re duction in prostaglandin le ve ls, deve lope d a ulcerating¯at re ctal ade nocarcinoma despite the abse nce of polypoid ade nomas 35 months after starting sulindac. O ther patie nts deve loping rectal cance r while on sulindac therapy have bee n re porte d (33, 34) . In addition, inve stigators have que stione d the importance of prostaglandin inhibition in colore ctal chemopre ve ntion. Ahne n e t al (26) note d that the sulfone metabolite of sulindac (FGN-1) inhibite d e xpe rimental colon carcinoge ne sis in the rat by a prostaglandin-inde pe nde nt proce ss (26) . Furthe r inve stigation reve aled reduce d tumor incide nce, multiplicity, and tumor burde n in sulindac sulfone -tre ated rats compare d to controls (36) . Moreover, there was no de crease in PGE 2 or signi® cant inhibitory e ffects on cyclooxyge nase , lipoxyge nase or phospholipase A 2 (36) . These obse rvations are supporte d by Hanif e t al, who note d, in colore ctal cance r cell line s, that growth inhibition was not associate d with prostaglandin inhibition (27) . Similar ® ndings have be en note d with sulindac sulfone in murine mode ls of mammary carcinoma (37) . The uncoupling of prostaglandin leve ls from carcinoge nesis raises the possibility that othe r bioche mical effects of NSAIDs are important. Sulindac has be en shown to incre ase apoptosis without changing the prolife rative rate as measure d by immunohistoche mistry for prolife rating cell nucle ar antige n (35) . There fore , NSAIDs may have re gulatory effects on the apoptotic pathway inde pende nt of prostaglandin synthe sis.
O ur re sults sugge st that future work e valuating an array of che moprote ctive compounds should include an analysis of prostaglandin leve ls to de te rmine if the se metabolite s are affe cted in unpre dicte d ways. Long-te rm studie s are also nee ded to corre late the de velopm ent of human colore ctal ne oplasia with mucosal prostaglandin le vels on a longitudinal basis in patie nts randomize d to prostaglandin inhibitory drugs and place bo.
